Federal Register / Vol. 79, No. 212 / Monday, November 3, 2014 / Notices 65219 

may have resulted in undocumented 

radiation exposures, characterizing 

radiological protection and monitoring 

practices, and identify co-workers and 

other witnesses as may be necessary to 

confirm undocumented information. In 

this process, NIOSH uses a computer 

assisted telephone interview (CATI) 

system, which allows interviews to be 

conducted more efficiently and quickly 

as opposed to a paper-based interview 

instrument. Both interviews are 

voluntary and failure to participate in 

either or both interviews will not have 

a negative effect on the claim, although 

voluntary participation may assist the 

claimant by adding important 

information that may not be otherwise 

available. NIOSH is requesting a three 

year approval for these data collection 

activities. 

NIOSH uses the data collected in this 

process to complete an individual dose 

reconstruction that accounts, as fully as 

possible, for the radiation dose incurred 

by the employee in the line of duty for 

DOE nuclear weapons production 

programs. After dose reconstruction, 

NIOSH also performs a brief, voluntary 

final interview with the claimant to 

explain the results and to allow the 

claimant to confirm or question the 

records NIOSH has compiled. This will 

also be the final opportunity for the 

claimant to supplement the dose 

reconstruction record. Approximately 

4,200 claimants will be interviewed 

with an average burden of one hour per 

response. 

At the conclusion of the dose 

reconstruction process, the claimant 

submits a conclusion form to confirm 

that the claimant has no further 

information to provide to NIOSH about 

the claim at this time. The form notifies 

the claimant that signing the form 

allows NIOSH to forward a dose 

reconstruction report to DOL and to the 

claimant, and closes the record on data 

used for the dose reconstruction. 

Signing this form does not indicate that 

the claimant agrees with the outcome of 

the dose reconstruction. The dose 

reconstruction results will be supplied 

to the claimant and to the DOL, the 

agency that will utilize them as one part 

of its determination of whether the 

claimant is eligible for compensation 

under the Act. It is estimated that 8,400 

claimants will complete the conclusion 

form which takes approximately 5 

minutes per response. 

The total estimated burden hours are 

4,900. There is no cost to respondents 

other than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

Claimant ............................................ Initial interview .................................. 4,200 1 1 4,200 

Claimant ............................................ Conclusion form OCAS–1 ................ 8,400 1 5/60 700 

Total ........................................... ........................................................... ........................ ........................ ........................ 4,900 

Leroy A. Richardson, 

Chief, Information Collection Review Office, 

Office of Scientific Integrity, Office of the 

Associate Director for Science, Office of the 

Director, Centers for Disease Control and 

Prevention. 

[FR Doc. 2014–26032 Filed 10–31–14; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60-Day 15–15CK] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

The Centers for Disease Control and 

Prevention (CDC), as part of its 

continuing effort to reduce public 

burden, invites the general public and 

other Federal agencies to take this 

opportunity to comment on proposed 

and/or continuing information 

collections, as required by the 

Paperwork Reduction Act of 1995. To 

request more information on the below 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, call 404–639–7570 or send 

comments to Leroy A. Richardson, 1600 

Clifton Road, MS–D74, Atlanta, GA 

30333 or send an email to omb@cdc.gov. 

Comments submitted in response to 

this notice will be summarized and/or 

included in the request for Office of 

Management and Budget (OMB) 

approval. Comments are invited on: (a) 

Whether the proposed collection of 

information is necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(b) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (c) ways to enhance the 

quality, utility, and clarity of the 

information to be collected; (d) ways to 

minimize the burden of the collection of 

information on respondents, including 

through the use of automated collection 

techniques or other forms of information 

technology; and (e) estimates of capital 

or start-up costs and costs of operation, 

maintenance, and purchase of services 

to provide information. Burden means 

the total time, effort, or financial 

resources expended by persons to 

generate, maintain, retain, disclose or 

provide information to or for a Federal 

agency. This includes the time needed 

to review instructions; to develop, 

acquire, install and utilize technology 

and systems for the purpose of 

collecting, validating and verifying 

information, processing and 

maintaining information, and disclosing 

and providing information; to train 

personnel and to be able to respond to 

a collection of information, to search 

data sources, to complete and review 

the collection of information; and to 

transmit or otherwise disclose the 

information. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

Improving the Impact of Laboratory 

Practice Guidelines (LPGs): A New 

Paradigm for Metrics—College of 

American Pathologists—NEW—Center 

for Surveillance, Epidemiology and 

Laboratory Services (CSELS), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

The Centers for Disease Control and 

Prevention is funding three 5-year 

projects collectively entitled ‘‘Improving 

the Impact of Laboratory Practice 

Guidelines: A New Paradigm for 

Metrics’’. An ‘‘LPG’’ is defined as 

written recommendations for voluntary, 

standardized approaches for medical 

laboratory testing that takes into account 

processes for test selection, sample 

mstockstill on DSK4VPTVN1PROD with NOTICES

65220 Federal Register / Vol. 79, No. 212 / Monday, November 3, 2014 / Notices 

procurement and processing, analytical 

methods, and results reporting for 

effective diagnosis and management of 

disease and health conditions. LPGs 

may be disseminated to, and used by, 

laboratorians and clinicians to assist 

with test selection and test result 

interpretation. The overall purpose of 

these cooperative agreements is to 

increase the effectiveness of LPGs by 

defining measures and collecting 

information to inform better LPG 

creation, revision, dissemination, 

promotion, uptake, and impact on 

clinical testing and public health. The 

project will explore how these processes 

and their impediments and facilitators 

differ among various intended users of 

LPGs. Through this demonstration 

project, CDC seeks to understand how to 

customize LPG creation and promotion 

to better serve these intended users of 

LPGs. An important goal is to help 

organizations that sponsor the 

development of LPGs create a 

sustainable approach for continuous 

quality improvement to evaluate and 

improve an LPG’s impact through better 

collection of information. 

The CDC selected three organizations 

that currently create and disseminate 

LPGs to support activities under a 

cooperative agreement funding 

mechanism to improve the impact of 

their LPGs. The American Society for 

Microbiology, the Clinical and 

Laboratory Standards Institute, and the 

College of American Pathologists (CAP), 

will each use their LPGs as models to 

better understand how to improve 

uptake and impact of these and future 

LPGs. Only the CAP submission will be 

described in this notice. 

The CAP project will address two 

LPGs that are important to clinical 

testing: immunohistochemistry test 

validation (IHC) and an algorithm for 

diagnosing acute leukemia (ALA). The 

ALA LPG is being co-developed with 

the American Society of Hematologists 

(ASH). The intended users of the CAP’s 

IHC LPGs will include pathologists, 

clinical laboratory directors, and 

laboratory managers overseeing the IHC 

staining department. For the CAP’s ALA 

LPG the intended users are pathologists 

and hematologists overseeing testing for 

acute leukemia. Thus, all these 

professionals will be surveyed by CAP. 

Prior to entering into this cooperative 

agreement project with the CDC, the 

CAP had already completed a baseline 

IHC LPG information collection from 

laboratories that used IHC testing. 

Subsequent to this data collection, the 

CAP created and disseminated an IHC 

LPG in a peer reviewed journal. Because 

of this prior baseline assessment, the 

CAP will only need to collect postdissemination data. For their ALA LPG 

CAP/ASH Algorithm for Initial Work-Up 

of Acute Leukemia, the CAP will 

conduct both a baseline and a postdissemination survey. Because there are 

uncertainties concerning the specific 

focus group probes for the IHC LPG and 

the ALA LPG, this notice only provides 

a description of our collection of postdissemination information for the IHC 

LPG and the baseline ALA LPG. 

The CAP hopes to achieve an 80% 

response rate, or 2,668 out of 3,335 

potential respondents. This represents 

laboratories known to be currently 

performing IHC testing based upon their 

participation in CAP’s IHC proficiency 

testing (PT) program and 450 additional 

laboratories identified by CDC using 

previous CMS Part B reimbursement 

claims for IHC testing. The response rate 

for the baseline IHC survey was 

approximately 70% but through more 

focused promotion the CAP hopes to 

increase participation. We have 

identified a total of 3,335 (2,885 CAPaccredited + 450 non-CAP-accredited) 

laboratories that will be targeted by the 

IHC post-dissemination survey. 

CAP-accredited laboratories that are 

enrolled in IHC PT will receive surveys 

with their PT mailings. Non-CAPaccredited laboratories will be surveyed 

via the US postal system, with a faxback mechanism. 

The CAP will need to collect both 

baseline and post-guideline 

dissemination data for the ALA LPG. 

CAP will allow only one response per 

computer internet protocol address. The 

CAP has a database of pathologists who 

have indicated specialization in 

hematopathology; these 

hematopathologists will be invited to 

participate. The CAP hopes to achieve 

an 80% response rate with their 

individual data collections, or 880 (80% 

× 1100 pathologists listed in the CAP 

database). 

The baseline survey for the ALA 

guideline includes questions about 

individual practices for diagnosing 

various types of acute leukemia and 

individual and laboratory reporting 

practices. The link to the baseline 

survey for the ALA guideline will be 

disseminated via email to 

hematopathologists in CAP’s database, 

who will be provided a link to the 

Qualtrics site that hosts the survey. 

The CAP and CDC will strive to 

ensure a high response rate for their IHC 

and ALA surveys. CAP plans to 

advertise both surveys. Similarly, the 

CAP plans to maximize response rates 

for non-CAP-accredited laboratories by 

sending reminders through the US 

postal system. The CAP will also try to 

maximize response rates for the ALA 

survey by advertising it through various 

channels. 

For burden calculation, we assume 

one response per laboratory. We assume 

respondents for the IHC survey will 

include (1) pathologists, (2) laboratory 

directors, and (3) other laboratory 

managers of IHC laboratories, which 

may consist of graduate level scientists 

(Ph.D.s and Masters level), 

approximately in a 25%:25%:50% 

distribution, respectively. We assume 

respondents for the ALA surveys will 

include pathologists and hematologists 

that sign out cases, approximately in a 

95%:5% distribution, respectively. 

The IHC baseline survey, which was 

conducted prior to this CAP–CDC 

cooperative agreement, took 15 minutes 

to complete. The IHC postdissemination survey and the ALA 

baseline survey are also expected to take 

15 minutes. Each survey will be pilot 

tested with nine or fewer respondents 

before deployment to assure that they 

require 15 minutes or less to complete. 

CDC is requesting a one-year OMB 

approval to collect the information. 

There are no costs to respondents other 

than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form 

name Number of respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

Pathologist .......................................................................................... IHC 834 1 15/60 209 

ALA 1,045 2 15/60 523 

Laboratory Directors ........................................................................... IHC 834 1 15/60 209 

Laboratory Managers .......................................................................... IHC 1,667 1 15/60 417 

Hematologist ....................................................................................... ALA 55 2 15/60 28 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 79, No. 212 / Monday, November 3, 2014 / Notices 65221 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Type of respondent Form 

name 

Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

Total ............................................................................................. ........................ ........................ ........................ 1,386 

Leroy A. Richardson, 

Chief, Information Collection Review Office, 

Office of Scientific Integrity, Office of the 

Associate Director for Science, Office of the 

Director, Centers for Disease Control and 

Prevention. 

[FR Doc. 2014–26030 Filed 10–31–14; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the Board 

of Scientific Counselors, NIDA. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Institute on Drug Abuse, 

including consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, NIDA. 

Date: November 20, 2014. 

Closed: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: Intramural Research Program, 

National Institute on Drug Abuse, NIH, Johns 

Hopkins Bayview Campus, Baltimore, MD 

21223. 

Contact Person: Joshua Kysiak, Program 

Specialist, Biomedical Research Center, 

Intramural Research Program, National 

Institute on Drug Abuse, NIH, DHHS, 251 

Bayview Boulevard, Baltimore, MD 21224, 

443–740–2465, kysiakjo@nida.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos.: 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: October 28, 2014. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–26025 Filed 10–31–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the Joint meeting of 

the National Cancer Advisory Board 

(NCAB) and NCI Board of Scientific 

Advisors (BSA). 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

A portion of the Joint NCAB/BSA 

meeting will be closed to the public in 

accordance with the provisions set forth 

in section 552b(c)(6), Title 5 U.S.C., as 

amended for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Cancer Institute, including 

consideration of personnel qualification 

and performance, and the competence 

of individual investigators, the 

disclosure of which would constitute a 

clearly unwarranted invasion of 

personal privacy. 

Name of Committee: National Cancer 

Advisory Board; ad Hoc Subcommittee on 

Global Cancer Research. 

Open: December 1, 2014, 6:00 p.m. to 7:30 

p.m. 

Agenda: Discussion on Global Cancer 

Research. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, Bethesda, Maryland 

20814. 

Contact Person: Dr. Edward Trimble, 

Executive Secretary, NCAB ad Hoc 

Subcommittee on Global Cancer Research, 

National Cancer Institute, National Institutes 

of Health, 9609 Medical Center Drive, Room 

3W–562, Bethesda, MD 20892, (240) 276– 

5796, trimblet@mail.nih.gov. 

Name of Committee: National Cancer 

Advisory Board and NCI Board of Scientific 

Advisors. 

Open: December 2, 2014, 8:30 a.m. to 5:15 

p.m. 

Agenda: Joint meeting of the National 

Cancer Advisory Board; and NCI Board of 

Scientific Advisors; NCI Board of Scientific 

Advisors Concepts Review, NCI Director’s 

report, and presentations. 

Place: National Institutes of Health, 9000 

Rockville Pike, Building 31, C Wing, 6th 

Floor, Conference Room 10, Bethesda, MD 

20892. 

Closed: December 2, 2014, 5:15 p.m. to 

6:00 p.m. 

Agenda: Review of intramural program site 

visit outcomes and the discussion of 

confidential personnel issues. 

Place: National Institutes of Health, 9000 

Rockville Pike, Building 31, C Wing, 6th 

Floor, Conference Room 10, Bethesda, MD 

20892. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 9606 

Medical Center Drive, Room 7W–444, 

Bethesda, MD 20892, (240) 276–6340. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. Information is also available on the 

Institute’s/Center’s home page: NCAB: 

http://deainfo.nci.nih.gov/advisory/ncab/

ncab.htm, BSA: http://deainfo.nci.nih.gov/

advisory/bsa/bsa.htm, where an agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

mstockstill on DSK4VPTVN1PROD with NOTICES